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Abstract
Background: Despite the availability of a dual therapy treatment protocol and infant feeding guidelines designed
to prevent mother to child transmission (PMTCT) of HIV, of the over 1 million babies born in South Africa each
year, only 70% of those born to HIV positive mothers receive dual therapy. Similar to other resource-poor nations
facing the integration of PMTCT into routine pregnancy and infant care, efforts in South Africa to scale up PMTCT
and reduce transmission to < 5% have fallen far short of the United Nation’s goal of 50% reductions in paediatric
HIV by 80% coverage of mothers.
Methods/Design: This study proposes to evaluate the impact of combining two evidence-based interventions: a
couple’s risk reduction intervention with an evidence based medication adherence intervention to enhance male
participation in combination with improving medication and PMTCT adherence in antenatal clinics to increase
PMTCT overall reach and effectiveness. The study will use a group-randomized design, recruiting 240 couples from
12 clinics. Clinics will be randomly assigned to experimental and control conditions and effectiveness of the
combined intervention to enhance PMTCT as well as reduce antenatal seroconversion by both individuals and
clinics will be examined.
Discussion: Shared intervention elements may decrease sexual risk and enhance PMTCT uptake, e.g., increased
male participation, enhanced communication, HIV counselling and testing, adherence, serostatus disclosure,
suggest that a combined sexual risk reduction and adherence intervention plus PMTCT can increase male
participation, increase couples’ communication and encourage adherence to the PMTCT process. The findings will
impact public health and will enable the health ministry to formulate policy related to male involvement in PMTCT,
which will result in PMTCT.
Trial registration: PACTR201109000318329
Background
Despite the availability of a dual therapy treatment pro-
tocol (Nevirapine + AZT) and infant feeding guidelines
designed to prevent mother to child transmission
(PMTCT) of HIV, of the over 1 million babies born in
South Africa each year, only 70% of those born to HIV
positive mothers receive dual therapy [1]. Similar to
other resource-poor nations facing the integration of
PMTCT into routine pregnancy and infant care, efforts
in South Africa to scale up PMTCT and reduce
transmission to < 5% have fallen far short of the UN
goal of 50% reductions in paediatric HIV by 80% cover-
age of mothers [2]. Bringing transmission rates below
5% represents potentially saving 75,000 babies of the
300,000 exposed to HIV annually. Mpumulanga Pro-
vince, the focus of the current application, has consis-
tently had one of the lowest rates of PMTCT; 69% of
pregnant women received PMTCT services in 2009.
Despite increases in uptake in other regions [3] Mpuma-
langa has the highest HIV prevalence (4.5%) among chil-
dren (0-18 years) in South Africa [4]. PMTCT program
failure occurs at all stages of the process in South Africa
[5]. Implementation of PMTCT programs in already
overburdened clinical settings presents multiple
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any medium, provided the original work is properly cited.challenges, including systemic (e.g., failure to offer ARV
prophylaxis, home delivery), social (e.g., stigma, lack of
disclosure), individual (e.g., maternal failure to ingest
medication or provide it to the infant, failure to obtain
antenatal testing) and interpersonal (e.g., lack of male
involvement, intimate partner violence) factors. Increas-
ing male participation as a method to enhance imple-
mentation of PMTCT and increase uptake of and
commitment to the medical protocol for pregnancy and
newborn care has been identified as a potentially critical
strategy for PEPFAR countries [6,7]. This application
proposes an implementation strategy to test whether
male involvement will increase PMTCT uptake utilizing
the existing public health program linking antenatal
HIV Counselling and Testing (HCT) and PMTCT
services.
Male involvement is also essential due to a related
issue, the disturbingly high rate of HIV seroconversion
(3%) during pregnancy in South Africa [8]. This suggests
the continuation of unprotected high risk sex during the
middle to latter stages of pregnancy may go undetected
for the purposes of PMTCT unless women are re-tested
just prior to delivery [9]. Again, male involvement in the
antenatal/HCT process may also influence and reduce
risk of HIV exposure during this critical period. Preven-
tion of Mother to Child Transmission (PMTCT) has
played the major role in reducing child mortality asso-
ciated with HIV/AIDS and improving maternal health
[10,11]. Guidelines for the use of antiretroviral therapies
to reduce transmission have been implemented in the
most HIV affected countries, especially those in sub-
Saharan Africa [12]. The PMTCT program in South
Africa consists of comprehensive counselling, HIV-test-
ing and the offer of ARV prophylaxis for seropositive
mothers and their newborns and referral of HIV positive
mothers and their families for CD4 count assessment for
antiretroviral therapy [10]. However, despite the wide-
spread availability of PMTCT, not all mothers provided
with medication take it themselves or provide it to their
newborns [13-17] due to a variety of circumstances,
including unwillingness or perceived inability to disclose
their HIV status to their partners [18]. Mother to child
transmission rates range from 12% to > 20% in South
Africa and drop out is high at all stages of the PMTCT
process [1].
To date, HCT for pregnant women has largely been
organized on an individual and sex-specific basis in
PMTCT programs, typically ignored by male partners.
However, a couples approach to HCT and antenatal
care facilitates communication about HIV serostatus,
thereby reducing one of the major barriers to accep-
tance of ARV prophylaxis by mothers for themselves
and their newborns, as well as encouraging adoption of
preventive behaviours within couples to reduce HIV
incidence during pregnancy [19] The need for male
involvement in the PMTCT process has been increas-
ingly encouraged to improve adherence to ARV prophy-
laxis [20,21] though no randomized clinical trials of the
influence of male partners as key contributors to accep-
tance and PMTCT uptake have been conducted. HCT
and prevention strategies for couples in stable relation-
ships could also strengthen HIV prevention efforts [22]
in Southern Africa, where the majority of HIV infections
occur in stable relationships. Prevention programs to
increase male involvement in Tanzania, Botswana and
Zambia have met with some success, e.g., Tanzania
found male involvement increased NVP uptake [23],
Botswana utilized a media campaign and increased male
involvement from 4% to 11%, and Zambia utilized
monetary incentives and couples counselling and
increased male involvement in PMTCT [24]. In Cote
d’Ivoire, prenatal couple counselling and testing
improved couples’ communication on sexual risks
among both HIV positive and negative women [25]. In
Kenya, partner participation in HCT and couples coun-
selling increased Nevirapine and formula feeding uptake
among women attending antenatal clinics [26] and part-
ner attendance to 15% [27,28]. In Rwanda and Zambia,
c o u p l e sH C Tl e dt oe n h a n c e df o l l o wu pa m o n gp r e g -
nant women at both sites but did not increase Nevira-
pine uptake [29]. However, while PMTCT attendance by
both members of a couple is feasible [23], uptake
remains limited by lack of male participation [29] high-
lighting the need to increase communication within the
couple about reproduction and sexual health [30]
Men’s attitudes regarding involvement in PMTCT and
antenatal care (ANC) programs have been linked to cul-
tural barriers, including the perception that male partici-
pation in ANC/PMTCT services is superfluous and that
ANC is “aw o m a n ’s responsibility” [30,10]. Additionally,
m e ni nT a n z a n i aw e r ef o u n dt oh a v eg e n e r a lH I V
knowledge but to lack specific information regarding
PMTCT and unable to attend PMTCT programs due to
timings which conflict with their work schedules. Simi-
larly, in Zambia, men were perceived as decision makers
in the home and felt their position was undermined if
they were expected to attend a “women’sc l i n i cp r o -
gram”, leading them to decline to attend ANC and
PMTCT with their partners [24], with as few as 2%
attending urban ANC (personal communication, Provin-
cial Health Office, Lusaka, Zambia). In Botswana, men
regarded ANC health facilities as being “generally
unfriendly” to them. Most recently, a review of studies
incorporating men suggested that male “support” as well
as “involvement” is key to increasing PMTCT uptake
[31]
As noted, 3% of women in South Africa seroconvert
during pregnancy following receipt of HIV negative test
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close their serostatus [32] or protect an uninfected part-
ner [33] These data highlight the urgent need to
incorporate strategies in conjunction with the PMTCT
process to prevent HIV transmission to mothers during
pregnancy [34,35]. This team’s previous research in the
US and Zambia has found that a gender specific group,
sexual behaviour intervention designed to increase cou-
ples communication, the Partner Project,e n h a n c e dt h e
acceptability and use of sexual barrier products (male
and female condoms) among HIV seropositive men [36]
and women [37,38]. We also increased need for multiple
session interventions among those in serodiscordant
relationships, who appear to represent a unique popula-
tion within those couples living with HIV [39]. The
Partner Project, currently being implemented in com-
munity health clinics across Zambia by CDC Zambia,
has achieved 95-100% retention of enrolled couples over
6 months and 90-95% over 12 months and maintained
comparative levels of participation by both men and
women throughout the intervention.
Aim of the study
The aim of the study is to evaluate the impact of com-
bining two evidence-based interventions: a couple’sr i s k
reduction intervention with an evidence based medica-
tion adherence intervention to enhance male participa-
tion in combination with improving medication and
PMTCT adherence in antenatal clinics (ANCs) to
increase PMTCT overall reach and effectiveness. The
s t u d yw i l lu s eag r o u p - r a n d o mized design, recruiting
240 couples from 12 clinics. Clinics will be randomly
assigned to experimental and control conditions and
effectiveness of the combined intervention to enhance
PMTCT as well as reduce antenatal seroconversion by
both individuals and clinics will be examined.
Objectives
Study objectives are to enhance PMTCT effectiveness by
1) increasing male partner participation in the PMTCT
process, 2) increasing male HCT, 3) increasing maternal
and infant adherence to the overall PMTCT protocol
and 4) increasing the use of sexual barriers and reducing
HIV transmission to mothers during pregnancy.
Methods/Design
Setting
Gert Sibande District (pop. 890,699, 71 PMTCT sites)
and Nkangala District (pop. 1,020,592, 80 PMTCT sites)
in Mpumalanga Province, continue to show evidence of
an increase in antenatal HIV prevalence from 32.1% in
2006 to 34.6% in 2007 to 35.5% in 2008 [2]. Gert
Sibande district had the highest antenatal HIV preva-
lence (38.9%) in Mpumalanga; 52% of those mothers
identified as positive took Nevirapine to prevent vertical
HIV transmission in 2006 [40]. HCT uptake overall is
70% in Mpumalanga province and below 50% in Gert
Sibande District. The delivery rate in health facilities is
approximately 70%, well below the South African aver-
age [41]. Clinic sites will be comparable by South Afri-
can criteria for PMTCT sites: on-site counselling and
testing for HIV & private room for HCT; daily availabil-
ity of HCT; referral to ARV site & CD4 count testing;
ARV prophylaxis; antenatal counselling on infant feed-
ing; postnatal counselling and support for infant feeding
& free infant formula; PCR testing for infants for HIV;
at least two trained PMTCT staff and two lay counsel-
lors; and a support group specific to HIV-positive
mothers and pregnant women.
Design
This study is a group-randomized controlled trial using
a 2 × 6 comparison (Clinic, Experimental, Control ×
Time, Baseline, Post-Intervention, Pre-delivery 32 weeks,
Pre-delivery day, Delivery, Post Partum). Twelve com-
munity health centres in communities within the Gert
Sibande and Nkangala Districts in Mpumalanga, South
Africa will be randomly assigned to condition in a 1:1
ratio. Six usual care condition clinics will provide the
standard of care, PMTCT; six experimental condition
clinics will offer PartnerPlus to mothers completing HIV
testing, regardless of serostatus, who are willing to enrol
with their male partners and participate in the inte-
grated PartnerPlus intervention. This study will recruit
240 couples (n = 480 individuals); community clinics
will recruit 2 cohort per clinic over 3 months (10 cou-
ples per cohort, n = 40, 120 individuals per condition)
(see Figure 1).
Study hypotheses
Hypothesis 1
Community clinics implementing PartnerPlus will have
more effective PMTCT program adherence, as measured
by maternal and paternal ANC and PartnerPlus visits,
maternal and paternal HCT uptake, maternal and infant
Nevirapine and AZT dose uptake, infant PCR, maternal
and infant HIV serostatus.
Hypothesis 1a
Community clinics implementing PartnerPlus will have
reduced sexual risk behaviour, as measured by partici-
pant sexual barrier use.
Principles for recruitment
Inclusion criteria
Community health centres with a high antenatal care
clinic case-load (based on statistics collected by the
Department of Health) in each of the two study districts
with a high burden of antenatal HIV will be included in
the study.
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Eligible participants will be male and female. Women: a)
pregnant women age 18 and older who have received
HCT at the ANC, b) willing to attend PartnerPlus or
PMTCT visits with their male partners, c) male partners
must also be available to participate and d) both part-
ners must be willing to participate in the study. Men: a)
men aged 18 and older who are partners of pregnant
women enrolled in the study, b) willing to attend Part-
nerPlus or PMTCT visits with their female partners, c)
female partners must also be enrolled in the study and
available to participate. All female participants must
have received HIV counselling and testing. In the event
that a participant has refused to know their status, they
will continue to be eligible as long as the results of test-
ing are provided to the study through clinic records. All
participants will be current adult residents of Mpuma-
l a n g aP r o v i n c ea n da g r e et oa t t e n df o u rg r o u ps e s s i o n s ,
2 psychosocial assessments and 1 within 7 days post-
delivery assessment (maternal and infant only - blood
sample assessment).
Exclusion criteria
Women who are not currently pregnant or are unwilling
to receive HCT are not eligible for this study. Women
whose partners are not willing to participate are not eli-
gible for this study. Men whose pregnant partners are
unwilling to participate are not eligible for this study.
Women and men who are not couples are not eligible
to participate. Participants unable to provide informed
consent will not be eligible.
Randomization
Clinics will be randomly assigned as PartnerPlus sites or
standard of care sites, stratified by antenatal care clinic
case load. Randomization will be conducted using a
secure remote randomization service. Each of the 2 com-
munities will have six community health centre sites par-
ticipating in the study. PartnerPlus community health
centres will offer the PartnerPlus (Partner plus PMTCT
standard of care); standard of care community health
centres will offer the standard of care, PMTCT, and a
time matched session. The time matched group session
will consist of a video on health education issues. Partici-
pants in both conditions will receive time matched inter-
ventions and identical compensation. Each clinic will
recruit a total of 1 cohort during a 3 month period.
Blinding
Participants (clinic staff members and clinic patients)
will not be blind to their intervention status. However,
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Figure 1 PartnerPlus Study Flowchart.
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behaviour and ARV adherence behaviour, the data col-
lection team who will assess the outcomes will be blind
to the clinic’s status as intervention or control interven-
tion arm.
Procedure
Men and women in the local community will be
recruited to work as “Peer Mentors” (men) and “Lay
Counsellors” (women) in the project. Recruitment of
Peer Mentors and Lay Counsellors will be done with the
assistance of nurses at the clinics, community leaders,
and HIV/AIDS coordinators at the district level, who
will be briefed on the objectives of the project. After
recruitment, Mentors and Counsellors will be trained
over five days on PMTCT, gender issues and facilitation
skills and 10 days in HCT, and will participate as group
leaders.
Participants (N = 240 couples) will be recruited in 2
communities through six community health clinics in
each community. At the ANC, following VCT, partici-
pants will be informed about the study and referred for
participation if interested. Following initial contact with
prospective participants, study staff will obtain a medical
and social (couple) history to determine initial eligibility
for the study. Couples will complete a couples status
verification questionnaire [42] Couples are interviewed
separately for couple eligibility, and are asked a short
series of rotating questions related to couple-specific
issues e.g., “w h os l e e p sn e x tt ot h ew i n d o w ?W h a tc o l -
our is your blanket?” Staff will compare responses to
access couple responses and qualify or disqualify couples
at this point. Couples are not notified of the reason for
ineligibility but are advised that they have not met elig-
ibility requirements, and are compensated for the visit
and thanked for their interest in the study. Those meet-
ing basic study criteria will be invited to provide and
sign the Informed Consent form. Participants will then
complete a baseline psychosocial and behavioural assess-
ment and be scheduled for their next visit. All question-
naire data are obtained by being read to the participants
to eliminate potential confounds related to literacy.
Consent
As participants can choose to participate in the inter-
vention or continue to receive the standard of care, it is
not necessary to consent the entire ANC patient popula-
tion in each clinic. Only women who have completed
HCT will be approached to participate in the study with
their male partners. Informed consent will be obtained
which will include permission to give the contact details
to the research staff, access to medical file information,
participate in the experimental or control condition,
tape recording of intervention sessions and psychosocial
interview and blood specimen collection assessment
procedures. To ensure comprehension of both literate
and illiterate participants, the informed consent will be
reviewed in detail (actually read to the prospective parti-
cipant in their primary language) and each study candi-
date will be asked to sign the form after agreeing to its
terms. Witnesses to consent will be drawn from study
staff. Participants will have been briefed on the nature
of the study prior to referral for informed consent.
Interventions
Standard of Care and health education videos
According to the South African guidelines for standard
of care all pregnant women should be routinely offered
HIV counselling and testing and encouraged to have
partner or spouse testing.
HIV seronegative. Following a negative HIV test,
women should have post-test counselling and counsel-
ling on risk reduction interventions including involve-
ment of partners or spouses, focusing mainly on how to
maintain their HIV-negative status. They should con-
tinue to receive routine antenatal care, and should be
encouraged to use condoms. They should be offered a
repeat HIV test at or around 32 weeks gestation, to
detect those who may have sero-converted during
pregnancy.
HIV seropositive. Following a seropositive HIV test,
p r e g n a n tw o m e ns h o u l db ea s s e s s e df o rC D 4a tt h e
laboratory. Women are routinely counselled on safer
sex, family planning, postnatal contraception and part-
ner testing. Women are provided with ARV regimens
for PMTCT. This is followed by a second visit, at which
time the clinic Physician may prescribe ARVs if WHO
guidelines for ARV introduction are met (CD4 < 350).
HIV seropositive patients are monitored by the health-
care worker at the antenatal clinic until 6 weeks post-
partum, at which time they are referred to the appropri-
ate facility.
Study participants, women and men, will view educa-
tional videos currently being used in the community
that address healthy living issues (e.g., nutrition, exer-
cise, relaxation). Participants in Usual Care will receive
t h eP M T C Tp r o t o c o lp l u st h et i m em a t c h e dg r o u p
administered presentation of health education videos.
Cognitive Behavioural Risk Reduction (CBRR) Group
Counselling Intervention
The Group intervention employs a closed, structured,
group intervention limited to 10 participants (women or
men). Four weekly, 11/2-2 hour sessions are led by a
trained gender-congruent counsellor and a peer facilita-
tor and emphasize group participation, cognitive-beha-
v i o u r a ls k i l lb u i l d i n g ,s e x u a ln e g o t i a t i o na n d
experimentation with products. The impact of alcohol
and drug use as direct and indirect contributors to high
risk behaviours is addressed. Participants receive cogni-
tive behavioural skill training on HIV/STD prevention
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cumcision and reproductive choice issues, communica-
tion, conflict resolution, sexual negotiation and an
educational/experiential program to increase use of and
adherence to sexual barriers. Information is presented
through multiple modalities (i.e., visual, auditory, experi-
ential) with ample opportunities for practice, feedback,
and reinforcement (e.g., discussion of methods of cir-
cumcision, reproductive choice, sharing experiences
using products with their partners, questions on product
use, opportunity to handle and examine products). Parti-
cipants are introduced to sexual barrier products (male
and female condoms) for the purpose of determining
cultural acceptability of such products to increase their
uptake. The content of the women’s and men’s interven-
tions include gender-relevant issues (e.g., relationships
and sexual negotiation), self management techniques (e.
g., learning to recognize antecedents of conflict and to
control impulses to engage in maladaptive and unpro-
ductive coping responses) and assertiveness training (e.
g., role plays to teach appropriate communication
strategies).
The intervention is guided by the theories of reasoned
action (intentions influence attitudes and subjective
norms which influence beliefs about behaviour; [43] and
planned behaviour (perceived behavioural control influ-
ences intentions and behaviour; [44] as predictors of
sexual barrier use [45]. Within this model, it is hypothe-
sized that sexual behavioural intentions and HIV-related
knowledge influence attitudes and perceived norms
regarding barrier use and partners, maladaptive coping
strategies, substance use and medication adherence. Per-
ceived sexual self efficacy, control of sexual behaviour
and barrier use will influence risk reduction strategies
and future sexual behaviour.
Session One addresses HIV/Sexually Transmitted
Infections (STIs), safer sex, barrier use, reproductive
choice and communication. Participants are advised of
standard rules regarding within-group confidentiality for
both participants and staff, stressing the restriction on
information overlap between gender groups. The use of
gender concordant therapists reduces the risk of disclo-
sure of group information. The HIV/STI and safer sex
segment informs the participants about the need for
safer sex regardless of serostatus (HIV transmission,
infection with HIV/STIs) and the health implications for
participants and their partners. This segment includes a
discussion of the hierarchical method of sexual barrier
use [46,47]. Male and female condoms are introduced as
the most effective forms of sexual protection. This is fol-
lowed by “hands-on” demonstrations of both products,
including practice with placing male and female con-
doms on/in models. The female condom is also illu-
strated with anatomical charts to clarify procedures for
insertion. All available options for protecting against
HIV infection are discussed in this session. For example,
male circumcision will be noted as one means of redu-
cing risk of HIV infection. Cognitive/behavioural skill
training and communication skills in relationships [48]
are introduced in the context of awareness building and
cognitive reframing, heightening participants’ awareness
of their reactions to barrier use in their sexual relation-
ships and reframing automatic thoughts that may
impede barrier use and communication [49]. Partici-
pants will learn self management techniques (e.g., learn-
ing to recognize antecedents of conflict). At the
conclusion of the session, participants complete a confi-
dential sexual diary to record their sexual behaviour and
use of barriers. Sexual diary entries are not discussed
during groups. Participants receive and are encouraged
to use a week’ss u p p l yo fm a l ea n df e m a l ec o n d o m s ;
handouts are provided on male and female condoms
and reproductive choice.
Session Two begins with participants’ completion of
sexual diaries and a questionnaire assessing the accept-
ability of male and female condoms. The session follows
a similar format to Session One Cognitive/behavioural
skill building focuses on sexual negotiation and open
communication techniques in relationships and the
influences of family. At the end of the session, partici-
pants receive a week’ss u p p l yo fm a l ea n df e m a l e
condoms.
Session Three begins with participants’ completion of
sexual diaries and a questionnaire assessing the accept-
ability of the products. Participants are encouraged to
discuss their experiences with the products, and the reac-
tions of partners and problems encountered. The group
process facilitates the sharing of experiences by those
who have tried the products to encourage those who
have not. The session addresses the potential for enga-
ging in high risk sexual behaviour when under the influ-
ence of alcohol and/or drugs. Skill building focuses on
sexual negotiation, influencing [50] and positive commu-
nication (e.g., expressing appreciation, avoiding blaming
and contempt, domestic violence [51,52]. Cognitive/
behavioural skill training exercises and role plays use the
experiences of the participants in problem solving and
cognitive restructuring, and participants are guided in
applying cognitive restructuring skills to practicing safer
sex and improving communication [53]. At the close of
the session, participants receive a weeks’s supply of their
most preferred products male and female condoms.
Session Four begins with participants’ completion of
sexual diaries, sexual barrier attitudes and behaviours,
and psychosocial questionnaires. This session focuses on
conflict resolution [54] communication and sexual nego-
tiation within the relationship. Videos and role playing
are used to illustrate elements of open successful
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tion, such as negativity, escalation and invalidation. Par-
ticipants are trained in communication with empathy,
increased positive messages and the reduction of nega-
tive verbal messages. At the close of the session, partici-
pants receive a month’s supply of their most preferred
products. Participants will be advised that they can
come to the study site to receive up to one month’s sup-
ply of barrier products each month for the duration of
their participation in the study.
Counsellor training and intervention quality assurance
Sites selected will have identified characteristics needed
for successful implementation, including patient volume,
space, staff and potential for sustainability [55]. These
characteristics will be reviewed prior to study onset, and
ongoing staff clinic meetings will be used to assess and
respond to challenges as they arise.
Study personnel will undergo formal training in
recruitment, assessment, and intervention procedures.
Training includes in-depth review of all assessment mea-
sures, intensive review of the intervention manual, the
PMTCT protocol, and training in cognitive behavioural
intervention strategies used in the intervention.
Intervention and assessment fidelity will be maintained
by tape recording of intervention sessions and quality
control will be conducted with transcribed sessions.
Outcome Measures
Assessments Months 3-10. All study materials, e.g., con-
sent, assessment and intervention, will be translated into
the major local languages (Zulu, Swati, Ndebele). Both
participants and clinic sites will be assessed (see Assess-
ment Table 1). Participant assessments will include both
biological (clinic data) and psychosocial assessments at
study entry, post-PartnerPlus intervention, 32 weeks
prior to delivery, immediately prior to delivery, 3 days
post-delivery and 6 weeks post-delivery. All assessments
are based on barriers to PMTCT uptake and will be
interviewer administered to avoid exclusion based on lit-
eracy. Participants will receive R100 per assessment and
R50 per intervention session for time and transportation.
Biological Assessment
Clinic data
Patient record data on the standard of care for PMTCT
and HCT, including, 1) baseline HCT, HCT at 32 weeks
Table 1 Assessment Measures: Individual Participants [Maternal, Paternal, Infant]
Assessment Time
(mins)
PMTCT
Protocol
Pre-
enrolment
Screen
Base-
line
Post-
Intervention
32 wks pre
delivery
Delivery 3 days Post-
Delivery
6 weeks post-
Delivery
PMTCT Standard of Care
Protocol
HCT maternal 20 X
Maternal CD4 5X
ART 30 X
ARV prophylaxis 5X X
Paternal HCT 20 X
Paternal CD4 X
Maternal 32 wk. HCT 20 X X X
PCR - infant - HIV 5X X
Screening
Couples Verification 10 X
Biological Assessment
Maternal & infant ART & ARV
prophylaxis blood test
5 X
Psychosocial & Behavioural
Assessment
Demographics 5X X
PMTCT& HIV Knowledge 5X X
Adherence: 4 days
ART & ARV prophylaxis
5X X
Sexual diary: 7 days 5X X
Sexual Risk Behaviour: 1 month 10 X X
Stigma 10 X X
Intimate Partner Violence: 1
month, lifetime
5X X
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PMTCT), 2) HCT for male partners (standard of care,
HCT) and 3) HIV testing by PCR at 6 weeks for infants
(standard of care, PMTCT).
ARV uptake assessment
Maternal and infant blood samples will be collected
within 7 days post- delivery using dried blood spots
(DBS). Samples will be analyzed to obtain a quantitative
assessment of the presence of Nevirapine, Zidovudine,
Efavirenz, Lamivudine, Stavudine, Lopinavir, Tenofovir
and Emtricitabine, the current medication regimens for
HAART and PMTCT in South Africa.
Assessment of Site Characteristics & Participants:
Maternal, paternal & infant
Site: Organizational Characteristics for PMTCT services
[55].
Participants: Session attendance, PMTCT visit atten-
dance, HIV testing.
Demographics (includes family composition, serostatus
disclosure, HIV status).
HIV and PMTCT Knowledge.
Adherence (Self reported ARV uptake - 4 days (ACTG
4-day Adherence Self Report measure) [56].
Sexual Risk (Sexual Risk Behaviour Scale) [57] Sexual
Barrier Use (Sexual Diary).
Stigma (Stigma Indicators Scale).
Intimate Partner Violence (Conflict Tactics Scale) [58].
Analysis approach
Statistical analysis
The goal of this study is to combine an effective sexual
risk reduction intervention with an effective medication
adherence intervention to increase adherence to the
PMTCT protocol. Clustering has been used due to the
anticipated observed intercorrelations within the clinics.
The sample size has been estimated as 1 + (m-1) p, m
being the average cluster size and p being the intraclus-
ter correlation coefficient. All comparisons will use an
alpha (two-tailed) of 0.05. Baseline characteristics will be
described using medians and interquartile ranges for
continuous variables and percentages with binomial
confidence intervals for categorical variables. This is a
group-randomized study that randomly assigns 12 sites
with 10 couples per site to either the intervention arm
or the control arm in a 1:1 ratio.
Hypothesis 1 Community clinics implementing Part-
nerPlus will have more effective PMTCT program
adherence, as measured by maternal and paternal ANC
and PartnerPlus visits, maternal and paternal HCT
uptake, maternal and infant Nevirapine and AZT dose
u p t a k e ,i n f a n tP C R ,m a t e r n a la n di n f a n tH I V
serostatus.
Hypothesis 1a Community clinics implementing Part-
nerPlus will have reduced sexual risk behaviour, as mea-
sured by participant sexual barrier use.
Analytic Plan 1 & 1a We will use a general estimating
equations (GEE) model to perform a Poisson regression
to test whether the likelihood of ANC attendance is sig-
nificantly higher in the intervention arm than the con-
trol arm adjusting for the clustering effect (Primary
Hypothesis). Assuming that 80% of the men in the inter-
vention arm and 2% of the men in the control arm
a t t e n dA N Ca n dat w o - t a i l e dt e s ta tt h e0 . 0 5l e v e l ,w e
estimate the power to be 0.99 for a range of intracluster
correlation coefficients from 0.1 to 0.9 [59]. A linear
mixed model will be used to compute a repeated mea-
sures analysis of variance to compare pre and post sex-
ual risk scores between the intervention and control
groups adjusting for cluster effects (Secondary Hypoth-
esis). Contrasts will be used to test planned comparisons
of pre and post scores between groups and pre-post
change within and between groups.
Laboratory Methods
Specimen tracking Batches of specimens will be sent to
a laboratory at the University of Cape Town and will be
tracked through waybill procedures. Specimens and spe-
cimen tracking sheets with the Dry Blood Spots (DBS)
bar-code will be sent to the laboratory in transparent
zipper lock bags containing desiccant. Consecutively
numbered laboratory bar-codes will be assigned to the
specimens as they are received by the laboratory. The
specimen bar-codes will by matched to the bar-codes on
the laboratory tracking sheets. The specimen bar-code
number will also be scanned or typed into an excel
spreadsheet. The Guthrie cards will also be labelled with
the laboratory bar-code number. Laboratory managers
will perform a second quality control (matching bar-
codes to tracking sheets and examining specimen qual-
ity) and will sign-off the tracking sheets for laboratory
processing.
Detection of antiretroviral drugs
The presence of antiretroviral drugs in HIV positive
DBS samples will be confirmed by means of High Per-
formance Liquid Chromatography coupled to Tandem
Mass Spectrometry. Qualitative detection of Nevirapine,
Zidovudine, Efavirenz, Lamivudine, Stavudine, Lopinavir,
Tenofovir and Emtricitabine in DBS samples will be car-
ried out by a validated method using minor modifica-
tions of the method used by [60].
Ethical and research governance approval
We have received ethical approval from the Human
Sciences Research Council Research Ethics Committee
(Protocol REC No. 1/18/08/10), the University of Miami
Miller School of Medicine (Protocol No. 20100555), the
National Institute of Allergies and Infectious Diseases
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Page 8 of 10and the Provincial Department of Health of Mpuma-
langa, South Africa.
Project Timescales
The study will run for a period of 13 months beginning
in December 2010 to December 2011.
Discussion
Shared intervention elements may decrease sexual risk
and enhance PMTCT uptake, e.g., increased male parti-
cipation, enhanced communication, HCT, adherence,
serostatus disclosure, suggest that a combined sexual
risk reduction and adherence intervention plus PMTCT
can increase male participation, increase couples’ com-
munication and encourage adherence to the PMTCT
process. This intervention presents a method to imple-
ment a couples-based PMTCT intervention that simul-
taneously decreases sexual risk and increases adherence
to PMTCT uptake by increasing male involvement. The
intervention, PartnerPlus, combines an evidence-based
behavioural HIV risk reduction intervention, the Partner
Project, with an effective pharmacologic adherence
intervention to prevent mother to child transmission,
PMTCT. The findings will impact public health and will
enable the health ministry to formulate policy related to
male involvement in PMTCT, which will result in
PMTCT.
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